Equities Analysts Issue Forecasts for NTLA Q3 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – HC Wainwright issued their Q3 2025 earnings estimates for Intellia Therapeutics in a report issued on Wednesday, March 5th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($1.48) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ FY2025 earnings at ($5.71) EPS, Q1 2026 earnings at ($1.48) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.54) EPS and FY2026 earnings at ($5.67) EPS.

Several other analysts have also recently issued reports on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group restated a “sell” rating and set a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. BMO Capital Markets cut their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. Chardan Capital cut their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Finally, Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $10.35 on Friday. The stock has a market capitalization of $1.07 billion, a PE ratio of -1.90 and a beta of 1.97. Intellia Therapeutics has a 1 year low of $8.30 and a 1 year high of $32.00. The company’s 50-day simple moving average is $10.61 and its 200-day simple moving average is $15.19.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently modified their holdings of NTLA. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $25,000. Sterling Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.